Today, we want to share our analysis of Sesen Bio (SESN) with you. The company's stock price has declined by more than 35% since mid-June after the release of secondary offering news. However, the company has a debt-free balance sheet with ~50% of its market cap in cash, and its lead drug has shown strong results. So, let's consider this promising biotech in-depth.
Company description
Sesen Bio is a late-stage clinical biotechnology company headquartered in the Cambridge that concentrates on developing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company was founded